We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+23.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.39B
AUM Growth
+$47.2M
(+2%)
Cap. Flow
-$369M
Cap. Flow
% of AUM
-15.45%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
68
New
22
Increased
12
Reduced
15
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$125M |
| 2 |
Cigna
CI
|
+$89.6M |
| 3 |
AbbVie
ABBV
|
+$75.2M |
| 4 |
Danaher
DHR
|
+$61M |
| 5 |
HCA Healthcare
HCA
|
+$59.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$143M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$132M |
| 3 |
Teleflex
TFX
|
+$119M |
| 4 |
Labcorp
LH
|
+$84.7M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$82.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.83% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Neurocrine Biosciences
NBIX
$16.4B
| $43.4M | 1.82% |
355,770
-1,191,970
| -77% | -$132M |
|
27
Regeneron Pharmaceuticals
REGN
$79.1B
| $35.3M | 1.48% |
+56,550
| New | +$32.1M |
|
28
BioNTech
BNTX
$23.2B
| $33.6M | 1.41% |
+503,920
| New | +$25.2M |
|
|
ARNA
29
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $30.2M | 1.27% |
480,460
+44,120
| +10% | +$2.43M |
|
30
Humana
HUM
$43.7B
| $27M | 1.13% |
69,550
-134,320
| -66% | -$50.3M |
|
31
Zimmer Biomet
ZBH
$19B
| $23.7M | 0.99% |
204,301
-644,646
| -76% | -$74.3M |
|
|
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $22.3M | 0.93% |
401,040
-393,440
| -50% | -$16.8M |
|
33
Pacira BioSciences
PCRX
$991M
| $21.3M | 0.89% |
405,040
-482,330
| -54% | -$20.2M |
|
34
Charles River Laboratories
CRL
$12.6B
| $17.6M | 0.74% |
100,730
-483,890
| -83% | -$77.2M |
|
35
Adaptive Biotechnologies
ADPT
$3.91B
| $16.7M | 0.7% |
+345,370
| New | +$12.6M |
|
|
BLUE
36
DELISTED
bluebird bio
BLUE
| $15.9M | 0.67% |
20,126
-27,909
| -58% | -$21M |
|
37
Align Technology
ALGN
$12.5B
| $13.5M | 0.57% |
+49,290
| New | +$11.1M |
|
38
Merck
MRK
$317B
| $13.3M | 0.56% |
+180,581
| New | +$13.6M |
|
39
Vertex Pharmaceuticals
VRTX
$123B
| $7.44M | 0.31% |
+25,620
| New | +$6.95M |
|
|
SRGA
40
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $6.86M | 0.29% |
71,955
| – | – |
|
|
SDC
41
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $5.53M | 0.23% |
+700,000
| New | +$4.75M |
|
|
IMGN
42
DELISTED
Immunogen Inc
IMGN
| $5.52M | 0.23% |
+1,200,000
| New | +$5.1M |
|
43
Arcturus Therapeutics
ARCT
$177M
| $4.4M | 0.18% |
+94,200
| New | +$3.25M |
|
|
BMY.RT
44
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $3.99M | 0.17% |
1,115,000
-3,710,260
| -77% | -$13.4M |
|
45
Legend Biotech
LEGN
$3.69B
| $3.19M | 0.13% |
+75,000
| New | +$2.93M |
|
|
FUSN
46
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $2.62M | 0.11% |
+150,000
| New | +$2.61M |
|
47
Tenet Healthcare
THC
$21.1B
| $2.32M | 0.1% |
+128,239
| New | +$2.53M |
|
|
AKUS
48
DELISTED
Akouos Inc
AKUS
| $2.25M | 0.09% |
+100,000
| New | +$2.23M |
|
|
GBIO
49
DELISTED
Generation Bio
GBIO
| $2.1M | 0.09% |
+10,000
| New | +$2.23M |
|
|
RNAM
50
DELISTED
Avidity Biosciences
RNAM
| $1.41M | 0.06% |
+50,000
| New | +$1.44M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2020 Portfolio in Review
As of Q2 2020, HealthCor Management held 68 positions worth $2.39B, up 2% from $2.34B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $369M in Q2 2020, closing 18 positions and reducing 15 holdings. Its most notable exit was Haemonetics, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier, followed by Real Estate.
Against the trend, HealthCor Management opened a new position in Cigna worth $88.6M.
- HealthCor Management's largest Q2 2020 buy was Cigna: 472,360 shares worth $88.6M.
- HealthCor Management added most to Becton Dickinson in Q2 2020, an estimated $125M increase.
- HealthCor Management's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $132M.
- HealthCor Management fully exited Haemonetics in Q2 2020, selling an estimated $143M.
- HealthCor Management's ten largest holdings make up 47% of its $2.39B portfolio in Q2 2020.
- HealthCor Management opened 22 new positions and closed 18 in Q2 2020.
- HealthCor Management's portfolio value rose 2% quarter-over-quarter to $2.39B.
Based on HealthCor Management's 13F filing for Q2 2020, filed 14 Aug 2020.